StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC)

Investment analysts at StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Several other research firms have also weighed in on RVNC. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. HC Wainwright reissued a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a report on Friday, November 8th. Barclays lowered their price target on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Finally, Mizuho lowered their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Revance Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Trading Down 0.3 %

NASDAQ RVNC opened at $3.63 on Wednesday. The firm has a market cap of $378.94 million, a price-to-earnings ratio of -1.88 and a beta of 0.86. The company has a 50 day moving average of $3.41 and a 200-day moving average of $4.59. Revance Therapeutics has a 1-year low of $2.30 and a 1-year high of $7.56.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. On average, analysts forecast that Revance Therapeutics will post -1.57 earnings per share for the current year.

Institutional Trading of Revance Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Alpine Associates Management Inc. acquired a new stake in Revance Therapeutics during the 3rd quarter worth $21,605,000. State Street Corp grew its holdings in Revance Therapeutics by 6.6% during the 3rd quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock worth $12,632,000 after acquiring an additional 150,323 shares during the period. LMR Partners LLP acquired a new stake in Revance Therapeutics during the 3rd quarter worth $11,648,000. Charles Schwab Investment Management Inc. boosted its position in shares of Revance Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 790,837 shares of the biopharmaceutical company’s stock worth $4,104,000 after purchasing an additional 41,250 shares in the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in shares of Revance Therapeutics by 2.5% during the third quarter. Rice Hall James & Associates LLC now owns 730,190 shares of the biopharmaceutical company’s stock worth $3,790,000 after purchasing an additional 18,118 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.